Part I General Information Part II Hemorrhagic Procesesses Part III Thromotic Procesesses Part IV Therapeutic Measures Part V Issues Specific To Women Part VI Special Issues
1 What is thrombosis ................................... 2 2 The mechanism of blood clot formation ............. 3 3 The causes of blood clot formation ......................... 5 4 Symptoms of …
2 Venue and contacts 3 Welcome message 5 Committees 17 Awards and grants 24 ISTH information
4 Message from the chairman 5 Meet the ISTH 6 Advanced training course program 9 Speakers 12 Program abstracts
Plenary session talks State of the art lectures Antithrombotic strategy in stroke
1. Physiology of hemostasis 2. clinical assesment of patients 3. Hereditary and acquired vascullar thrombohemmoragic disorders 4. Platelet function deffects 5 Thrombocytopenia and thrombocytosis
1722 The unique contribution of ion channels to platelet and megakaryocyte function 1733 Activated protein C reasons to believe 1736 Activated protein C modulates cardiac metabolism and augments …
1979. Phase III studies on novel oral anticoagulant for stroke prevention in atrial fibrillation a look beyond the excellent results 1988. Contemporary managementof primary immune thrombocytopenia…
2215 Regulators of G protein signaling role in hematopoiesis megakaryopoises and platelet function 2223 The evolution and value of bleeding assesment tools 2230 Anticoagulants in cancer 2242 Reg…
2418 The future of glycoprotein VI as an antiihrombotic target 2428 Von willebrand factor the old the new and the unknown 2438 Air pollution, vascular disease and thrombosis linking clinical data…